Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine in Infants and Children in Bangladesh
NCT06838195Phase 3Active, not recruiting
- Sponsor
- Zhifei Green Bamboo
- Start
- May 2025
- Primary completion
- Jul 2028
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine in Shigella infection (2 arms), sponsored by Zhifei Green Bamboo. Primary endpoint: Protective efficacy of S. Flexneri-S. Sonnei bivalent conjugate vaccine. Started May 2025; status: active, not recruiting.
02
Drugs
shigella flexneri 2a-shigella sonnei bivalent conjugate vaccine
03
Conditions
Shigella infection
Beyond the preview
Go deeper on NCT06838195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838195.